came from both an increase of Baht 468 million, or 2.93 percent in non-interest income, which was derived mainly from revenue from capital market products and rising net fees and service income, and an

Operation : Consolidated Profit & Loss Statement 4Q 4Q % 12 mth 12 mth % Unit : THB million 2019 2018 change 2019 2018 change Revenue from non-social security 285.64 220.70 29% 1,041.26 911.16 14% Revenue

statement for the year period ended December 31, 2018, details are as follows: The operating results of the consolidated financial statement for the year period ended December 31, 2018 The Consolidated

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

declined yoy whereas revenue per head remained on the rise. The increase of revenue per head was Operation : Consolidated Profit & Loss Statement 3Q 3Q % 9 mth 9 mth % Unit : THB million 2019 2018 change

auditor as follows: Statements of Comprehensive Income for the 2nd Quarter Ended June 30, 2020 Operation : Consolidated Profit & Loss Statement 2Q 2Q % Unit : THB million 2020 2019 change Revenue from Non

follows: Statements of Comprehensive Income for the 1st Quarter Ended March 31, 2020 Revenue from Hospital Operations Operation : Consolidated Profit & Loss Statement 1Q 1Q % Unit : THB million 2020 2019

Indorama Ven- tures Public Company Limited for the third quarter of 2017 We are pleased to submit: 1. Consolidated and Company only Quarterly Reviewed Financial Statements for the third quarter of 2017 (a

within 31 December 2018. The transaction mentioned above is considered as a disposal of assets in accordance with the Notification of the Capital Market Supervisory Board No. TorChor. 20/2551 (2008) Re

total registered capital) (“Prime-A”) amounted to 50,000 shares at the par value of Baht 100 per share, which is equivalent to 50 percent of the total shares in Prime-A; and assigned the claim on the